Americas

Argentina

Spanish

Brazil

Portuguese

Canada

Chile

Spanish

Colombia

Spanish

Mexico

Spanish

Peru

Spanish

United States

English

Asia Pacific

Europe

Austria

German

Belgium

Czech Republic

Czech

Denmark

Danish

Finland

Finnish

France

French

Germany

German

Greece

Greek

Hungary

Hungarian

Ireland

English

Italy

Italian

Luxembourg

English

Netherlands

Norway

Norwegian

Poland

Polish

Portugal

Portuguese

Romania

Romanian

Spain

Spanish

Sweden

Swedish

Switzerland

United Kingdom

English

Middle East

Israel

Hebrew

Saudi Arabia

Turkey

Turkish

United Arab Emirates

Other

Other Markets

Distributor Markets
Our Medicines
Scientific media resources
Diversity in clinical trials is a scientific imperative
Home / News and media / Media library / Scientific media resources / Diversity in clinical trials is a scientific imperative
August 01, 2024

Insights into how a particular disease might affect a diverse patient population are essential to the drug development process so researchers can create the most innovative treatments and interventions. By including a wide range of patients in our research who are impacted by a particular disease, regardless of their race, ethnicity, gender, disability status, sexual orientation and/or where they live, among other characteristics, we can help reduce health disparities.

Diversity in clinical trials is a scientific imperative


We seek to have patient populations in our clinical trials that are reflective of the real-world population and aligned with the epidemiology of the diseases we study. In doing so, we believe we can better address barriers to achieving health equity and deepen understanding of the safety and efficacy of transformative medicines for diverse populations.

Recognition of the need for more diverse representation has prompted an industry-wide effort for inclusive medical research

Recognition of the need for more diverse representation has prompted an industry-wide effort for inclusive medical research

How is Bristol Myers Squibb increasing clinical trial diversity?


As we continue assuring trials are designed with the right patient population in mind, we have taken a comprehensive approach in clinical trial diversity to focus on:

Protocol design

Protocol design considerations
Designing clinical trials considering diverse populations’ needs

Communication and engagement

Communications and engagement
Engaging with diverse stakeholders, including advocacy organizations, industry collaboratives, principal investigators, community outreach groups and trusted voices to foster sustainability and trust in clinical trials

Metrics and measures

Metrics and measures
Setting clear measures to track trial participant diversity for ongoing adjustments

Site and investigator

Site and investigator selection
Aiding trial sites and investigators in recruiting and retaining diverse participants and assuring research centers are more accessible to diverse populations

Patient Support

Patient support
Providing tailored services in an effort to understand and address barriers for participation

Training

Training
Investing in staff training to address diversity and inclusion in clinical trials, fostering an internal and external mindset shift and a culture of awareness

Our work to-date


BMS has ensured that studies are focused on medically underserved populations and that sites for our new studies include investigators in the most racially and ethnically diverse metro areas in the United States

Conducted 58% of BMS clinical trial sites in racially and ethnically diverse metro areas of the U.S. in 2023, surpassing our initial goal of 25% set in 2020 and making clinical trials more accessible to underrepresented groups

Stethoscope
Larger hands heart

Allowing adult patients in the U.S. to privately self-identify their sexual orientation, gender identity and intersex status (SOGIIS); focused on addressing health disparities affecting LGBTQ+ persons

Evolving our approach to focus on increasing the percentage of racially and ethnically diverse patients enrolled in clinical trials globally across key indications, including lupus, multiple myeloma, pulmonary fibrosis and Alzheimer’s disease

We recognize there is still work to be done.

We are committed to scientific excellence and investment in our R&D capabilities to provide more medicines to more patients faster. Our efforts to advance clinical trial diversity are aligned with BMS’ broader commitments to global inclusion and diversity and health equity.

AltStyle によって変換されたページ (->オリジナル) /